Search Research

A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab in Stage IV Squamous Cell Lung Cancer

Demographics (1)

SEX - Biological sex (phv00534914.v1.p1)

Other (4)

CONSENT - Consent group as determined by DAC (phv00534913.v1.p1)
SAMPLE_ID - Sample ID (phv00534916.v1.p1)
SUBJECT_ID - CIMAC Participant ID (phv00534912.v1.p1)
SUBJECT_ID - Subject ID (phv00534915.v1.p1)